
    
      Utilization of combination standard intravenous chemotherapy with intravenous pembrolizumab
      (for 6 cycles) in first line treatment of patients with advanced ovarian cancer post surgery
      with any residual disease. This will be followed by single agent intravenous pembrolizumab
      (every 3 weeks) for 12 additional cycles.
    
  